1928 Diagnostics empowers healthcare providers to swiftly identify and respond to antibiotic-resistant infections, thereby enhancing patient outcomes and contributing to global health efforts against antimicrobial resistance.
1928 Diagnostics AB, a Swedish health technology company, specializes in combating antibiotic resistance through advanced cloud-based software solutions. Their primary offering is a bioinformatics analytics platform designed to support microbiologists in maximizing the utility of sequencing data. This platform provides a cloud service for analyzing genomic data, facilitating outbreak tracing and identification of bacteria, viruses, and fungi worldwide. Notably, the platform is user-friendly, fast, and secure, serving customers across healthcare, food, and environmental sectors.
In collaboration with Genomic Medicine Sweden (GMS), 1928 Diagnostics has been instrumental in developing analytical tools aimed at preventing outbreaks of infectious bacteria. A significant joint project involved evaluating a more effective typing method for outbreak tracing of Methicillin-resistant Staphylococcus aureus (MRSA) using the 1928D analysis platform. This initiative encompassed all seven university hospitals within GMS, Ryhov Hospital in Jönköping, and the Public Health Agency of Sweden. The project facilitated real-time data sharing and enhanced the prevention of infectious bacterial outbreaks.
Expanding its reach, 1928 Diagnostics entered the U.S. market by launching its cloud service platform for microbial analysis during the annual Infectious Diseases Society of America (IDSA) meeting at IDWeek in Washington, D.C. This expansion aims to provide U.S.-based hospitals with tools to combat hospital-acquired infections effectively. The platform offers automated and robust DNA data analysis, enabling healthcare facilities to monitor and control the spread of multidrug-resistant bacteria, commonly known as superbugs.
Funding Comment:
1928 Diagnostics has secured approximately $8.45 million in funding over time. Notable investors include Hargay, Sciety, Horizon 2020 SME Instrument, Chalmers Innovation, and Chalmers Ventures. In 2014, the company received SEK 1,6 million from Vinnova, Sweden’s innovation agency, to accelerate product development and in 2018, 1928 Diagnostics was awarded SEK 15 million to further support its expansion.
